MK-677

Oral, once-daily growth hormone secretagogue. Technically a small molecule, not a peptide - but lumped into the category for protocol purposes.

MK-677 — non-peptide small molecule

Non-peptide small molecule (ibutamoren); MW ~528 Da. Acts as ghrelin receptor agonist orally.

Overview

MK-677 (also known as ibutamoren, mibutamoren, or Nutrobal) is a small molecule that mimics the action of ghrelin at the ghrelin receptor (GHSR-1a) in the pituitary and hypothalamus. Despite being grouped with "peptides" in common use, it is technically not a peptide - it's a small molecule with full oral bioavailability, which makes it distinctive in this category. A typical dose is once-daily oral, most often at bedtime.

Because it stimulates natural pulsatile GH release, MK-677 produces sustained elevation of both growth hormone and IGF-1, comparable to what tesamorelin produces via the GHRH pathway. Unlike injectable GHRH analogs, however, MK-677 also triggers endogenous ghrelin effects - increased appetite, measurable water retention, and some users experience transient elevation of cortisol and prolactin.

MK-677 is one of the compounds where careful biomarker tracking genuinely matters. It can modestly impair glucose tolerance in some users, which only shows up on fasting glucose and fasting insulin panels - not on weight or subjective measures. Anyone running it should pull these at baseline and 8-week marks at minimum.

Mechanism of Action

MK-677 activates the growth hormone secretagogue receptor (GHSR-1a), the endogenous receptor for ghrelin. This stimulates pulsatile endogenous GH release from the pituitary, increases IGF-1 production from the liver, and produces ghrelin-associated effects like increased appetite. Unlike GHRH analogs (tesamorelin, sermorelin), MK-677 acts further upstream and produces a broader endocrine effect - including the appetite and water-retention signals that come with ghrelin stimulation.

Community Usage Patterns

Standard dose is 25 mg oral once daily, typically at bedtime (many users find the compound makes them drowsy). Some users run 10 mg to minimize water retention and appetite effects. Cycles typically run 2–6 months, often with structured off-periods. Baseline IGF-1 is drawn before starting; response is assessed at the 4–8 week mark. Fasting glucose and insulin should be monitored - MK-677 is the peptide category compound most associated with insulin resistance in practical use.

Education only - not medical advice. Any protocol change should involve your licensed provider.

Deep Dive

A ghrelin mimetic with a built-in ceiling

MK-677 is a spiropiperidine, a fully synthetic small molecule rather than a peptide, which is why it survives digestion and works as a once-daily oral. Its more important distinction is functional. Because it amplifies the pituitary's own growth hormone pulses instead of delivering hormone directly, output stays under the body's normal brakes: the somatostatin tone that ends each pulse, and the negative feedback that rising IGF-1 exerts back on the pituitary. In practice this gives MK-677 a ceiling. It can raise growth hormone and IGF-1 toward a young-adult range, but it does not force them into the grossly supraphysiologic territory reached by injecting recombinant growth hormone. That feedback ceiling is the single biggest pharmacologic difference between a secretagogue and exogenous GH. It is a mechanism worth understanding with a licensed clinician, not a claim of benefit.

The same ghrelin receptor sits in appetite and stress-axis tissue, so the compound also nudges cortisol and prolactin upward. In the two-year Nass trial, mean cortisol rose about 1.7 micrograms per deciliter. Small short-term studies have also reported increased slow-wave and REM sleep, consistent with ghrelin's role in the nocturnal GH surge, though these are early-phase findings rather than durable outcomes.

What the human trials actually found, and did not

The endocrine proof of concept is solid. Chapman and colleagues (JCEM, 1996) showed that daily oral MK-677 produced sustained elevation of both growth hormone and IGF-1 in healthy older adults across the dosing window, driven by taller GH pulses rather than a single transient spike.

The most complete data come from Nass and colleagues (Annals of Internal Medicine, 2008), a two-year, double-blind, placebo-controlled trial in 65 healthy adults aged 60 to 81. MK-677 25 mg daily raised GH and IGF-1 into the young-adult range. Fat-free mass rose 1.1 kg versus a 0.5 kg loss on placebo, and body weight climbed 2.7 kg. The decisive finding, though, is that the added fat-free mass did not translate into any measured change in strength or function, and the compound also produced transient lower-extremity edema. Fasting glucose rose about 5 mg/dL and insulin sensitivity fell.

The Alzheimer's trial closes the loop. Sevigny and colleagues (Neurology, 2008) randomized 563 patients with mild-to-moderate disease to MK-677 or placebo for 12 months. Serum IGF-1 climbed roughly 73 percent by month 12, clear evidence the drug engaged its target, yet there was no benefit on any cognitive or functional endpoint.

The honest summary: robust randomized data show MK-677 reliably moves hormones, body composition, and bone-turnover markers. Across those same controlled trials it repeatedly failed to convert those shifts into strength, function, or clinical improvement. That translation gap is a large part of why it was never approved. Claims about recovery, injury healing, or anti-aging rest on anecdote rather than controlled endpoints.

Biomarkers commonly discussed around this compound

IGF-1 is the response marker, but in the trials it was read against an age-adjusted reference rather than treated as "higher is better." In those studies MK-677 raised IGF-1 into a young-adult range, not above it. IGF-1 pushed above the laboratory ceiling is where the risk-benefit picture gets murkier: population epidemiology links persistently high IGF-1 to higher rates of certain cancers, including colorectal, prostate, and breast. That is an association across large groups, not evidence that MK-677 causes cancer, but it is why supraphysiologic IGF-1 is not a sensible target.

Fasting glucose and fasting insulin are often looked at together because they can be combined into HOMA-IR (fasting insulin times fasting glucose divided by 405). Because the Nass trial documented rising glucose and falling insulin sensitivity, this pair is the metabolic readout most often flagged on the compound, and a drift in HOMA-IR is more informative than either number alone. HbA1c adds the roughly 90-day integrated view that a single fasting draw can miss.

Two signals that sit outside the standard panel are body weight and blood pressure. Nass recorded a 2.7 kg weight gain and transient edema, and rapid early weight gain is usually fluid. For anyone with a history of heart failure, that fluid-retention profile is a specific reason to involve a clinician before considering the compound. Prolactin and cortisol round out the secondary reads.

Why the metabolic drift is easy to miss

The metabolic effect is the one that changes quietly. Glucose and insulin can drift well before any subjective change, which is the entire rationale for organizing lab data over time rather than judging by how someone feels. Increased appetite and water retention are expected pharmacology, not a sign the compound is "working." None of this is a recommendation to obtain, dose, or self-administer anything. It is context for organizing data a person would review with a licensed clinician, who is the right party to weigh the metabolic and fluid effects against any individual history.

Regulatory and safety status

MK-677 has never been FDA-approved. Merck and later rights-holders ran the trials above and shelved the program once the functional endpoints failed. A distinction that gets blurred online: because MK-677 is a small molecule and not a peptide, it does not sit inside the FDA peptide-compounding pathways, and it has never been a legitimate compounded-pharmacy product. Material sold online typically carries "research chemical, not for human consumption" labeling, which means identity, dose accuracy, and purity are unverified by any regulator. Separately, the World Anti-Doping Agency lists growth hormone secretagogues, MK-677 included, on its Prohibited List under class S2 at all times, so it is disqualifying for tested athletes. Anyone weighing this compound should review the metabolic and fluid-retention profile with a licensed clinician first.

Biomarkers to Track

When running MK-677, these are the biomarkers most commonly tracked to assess response and safety:

Blood Work Checklist

Before starting MK-677, baseline the right panel. The Peptide Blood Work Checklist covers the full baseline panel, what to add for MK-677's class, and when to retest.

Reconstitution Calculator

Free calculator for MK-677 reconstitution math - vial size, BAC water volume, and exact syringe units.

Side Effects & Monitoring

What MK-677 side effects are commonly reported, when they appear, the red flags worth a provider call, and the biomarkers that catch issues early.

Results & What to Track

What MK-677 results actually look like in the data - the markers to measure, when they tend to move, and how to tell a real result from placebo.

Related Reading

• Igf 1 Blood Test Guide →

Related Peptides

MK-677 Head-to-Head Comparisons

Frequently Asked Questions

Log doses, upload your lab PDFs, and let StackAI read your panel in context of what you're actually running. Free to start.